Apothecary Pharma recalls compounded tirzepatide injections nationwide over sterility concerns
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
Apothecary Pharma, a Cary, North Carolina compounding pharmacy, voluntarily recalled compounded tirzepatide injections nationwide for lack of sterility assurance.
The FDA rated it Class II, so serious harm is considered unlikely but temporary reactions are possible.
Background
Apothecary Pharma LLC is a compounding pharmacy in Cary, North Carolina — a facility that mixes custom drug versions rather than selling manufactured brand products. Its recall covers compounded tirzepatide, the active ingredient in Eli Lilly's brand-name drugs Mounjaro and Zepbound. Compounded GLP-1s (a class of drugs used for weight loss and diabetes) drew consumers while Novo and Eli Lilly struggled to meet demand; the FDA declared shortages of semaglutide and tirzepatide ended in late 2024 and 2025, after which compounders were expected to stop mass production, but many continued, prompting FDA warnings and lawsuits from Lilly and Novo. Consumers sought compounded versions because they are typically less expensive, and fewer than half of large employer health insurance plans cover Wegovy and Zepbound for weight loss.
How it unfolded
- Dec 2025The FDA sent Apothecary Pharma a warning letter citing serious deficiencies in the company's sterile drug production practices, which the agency said put patients at risk.
- Sep 24, 2026Apothecary Pharma initiated a voluntary recall of compounded tirzepatide injections for "lack of assurance of sterility," notifying recipients by letter.
- Oct 8, 2026The FDA classified the recall as Class II, indicating serious health consequences are considered unlikely.
- Oct 10, 2026The FDA updated the recall listing as Class II, meaning use could cause "temporary or medically reversible adverse health consequences" with a small risk of serious harm.
- Oct 20, 2026Reports were published on the nationwide recall of 22 vials of compounded tirzepatide plus one vial of NAD+ injection.
- date unknownThe recall is listed as ongoing, with nationwide distribution.
Who’s saying what
- Official
- The FDA says the recall reason is lack of assurance of sterility, and that the listing does not establish contamination was found in every vial.
- Caution
- Erin Fox, senior pharmacy director at University of Utah Health, said patients should understand why they need a compounded version: "If it's just for price point, than it's absolutely buyer beware because you get what you pay for."
- Party
- NewLife Rx, a fulfillment service that distributed some recalled vials, said Apothecary told its team the recall was a documentation issue on a "retail level" that does not extend to patients or require them to stop using or return their medications.
Still unverified
Whether the recall covers 22 vials or 22 lots: the FDA says 22 vials, but the accompanying lot codes indicated it may actually be 22 lots, and USA TODAY has asked the FDA for clarity. NewLife Rx's statement that the recall was a documentation issue and does not require patients to stop using or return medications is also unconfirmed.